Dual GIP/GLP-1 receptor agonist with superior weight reduction outcomes vs semaglutide alone.
Activates both the GLP-1 receptor and the glucagon receptor. GLP-1 activity drives appetite and glycaemic effects, while glucagon-receptor activity is investigated for its influence on energy expenditure and hepatic fat. Still in clinical development rather than broad approval.
Active ingredient in Mounjaro and Zepbound. SURMOUNT-1 trial showed ~22% average body weight loss — significantly higher than semaglutide's ~15%.
The GIP component may contribute to improved tolerability, with some researchers reporting fewer GI side effects than pure GLP-1 agonists. GIP receptors are also expressed in bone and may have additional metabolic effects.